GlassScriptPhysician profile
Michael Trent Mcbride
NPI 1225284276
$1,338.08
in general payments reported to CMS, 2019-2025
10 companies · $115 in 2025
The $115 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $126 · 2022: $135 · 2023: $541 · 2024: $421 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $387.36 | 2023-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $314.30 | 2020-2023 | |
| Abbvie INC. | $255.97 | 2023-2025 | |
| Argenx US, INC. | $108.02 | 2023 | Vyvgart |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Dermavant Sciences, INC. | $64.11 | 2024 | Vtama |
| Kyowa Kirin, INC. | $40.44 | 2023 | Poteligeo |
| Leo Pharma INC. | $32.09 | 2023 | Adbry |
| Almirall LLC | $21.23 | 2023 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $14.57 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.